Inflammatory bowel disease (IBD), as a global disease, has attracted much research
interest. Constant research has led to a better understanding of the disease condition and …

Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of
neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous …

Background Approximately half the patients with ulcerative colitis who undergo restorative
proctocolectomy with ileal pouch–anal anastomosis (IPAA) will subsequently have pouchitis …

Inflammatory bowel disease (IBD), as a representative inflammatory disease, currently has
multiple effective treatment options available and new therapeutic strategies are being …

Background Biologic therapies are widely used in patients with ulcerative colitis. Head-to-
head trials of these therapies in patients with inflammatory bowel disease are lacking …

The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the
clinical and endoscopic remission of disease, reduce the incidence of complications such as …

Abstract Background and Aims This study aimed to compare real-world clinical effectiveness
and safety of vedolizumab, an α4β7-integrin inhibitor, and anti-tumour necrosis factor-α [anti …

Immune checkpoint inhibitors (ICPI), such as ipilimumab [anti-cytotoxic T-lymphocyte
antigen-4 (CTLA-4) antibody] and nivolumab or pembrolizumab [anti-programmed cell death …

Background Selective patient recruitment can produce discrepancies between clinical trial
results and real-world effectiveness. Methods A systematic literature review and meta …

Background & Aims Vedolizumab is effective and safe for the treatment of Crohn's disease
(CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response …